Anaplastic lymphoma kinase (ALK) is a member of the insulin receptor protein-tyrosine kinase superfamily.
ALK inhibitors, has substantially improved outcomes for patients with ALK-positive NSCLC. The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib.
(Will delete Record if Target field = "Delete") Home